title: Factors predicting intermediate endpoints of cervical cancer and exposure to human papillomavirus (HPV) infections in young women screened as potential targets for prophylactic HPV vaccination in south of Brazil.
abstract: OBJECTIVE
  To explore the predictors of intermediate endpoints of cervical cancer in 500 women living in Porto Alegre.
  
  
  METHODS
  Five hundred randomly selected women (mean age 20.3 years, range 15-25) were screened using PCR detecting 25 HPV types (HPV6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 70, and 74). Women were interviewed and serum samples were analysed for antibodies to HPV16 and HPV18 VLPs. Regression models were constructed to analyse predictive factors for (a) HPV PCR status, (b) HPV16-seropositivity, (c) HPV18-seropositivity, and (d) SIL in the PAP smear, used as intermediate endpoints of cervical cancer.
  
  
  RESULTS
  Specific HPV types were identified in 137 (27.4%) of the 157 (31.4%) PCR-positive women. PAP test result was the most powerful independent predictor of HPV status in PCR (p = 0.0001), followed by the sexual activity started (p = 0.001) (adjusted OR 34.075, 95% CI: 4.650-249.715). PAP test SIL was independently predicted only by the HPV PCR status (p = 0.0001) (OR 7.561, 95% CI: 2.787-20.514). HPV16 and HPV18 serostatus were the most significant predictors of each other (p=0.0001), and the life-time number of sexual partners was more significant (p=0.001) predictor of HPV16 than HPV18 serostatus (p = 0.049).
  
  
  CONCLUSIONS
  These data are useful in evaluating the exposure status of the women to the risk factors of cervical cancer in south of Brazil.
authors.affiliation: Hospital de Clinicas de Porto Alegre, Department of Obstetrics and Gynaecology, Universidade Federal do Rio Grande do Sul (UFRGS), Av. Nova York, 117/23 Auxiliadora, ZIP 90550-070 Porto Alegre, RS, Brazil.
authors.forename: P
authors.initials: P
authors.lastname: Naud
authors.forename: J
authors.initials: J
authors.lastname: Matos
authors.forename: L
authors.initials: L
authors.lastname: Hammes
authors.forename: J
authors.initials: J
authors.lastname: Stuckzynski
authors.forename: K
authors.initials: K
authors.lastname: Brouwers
authors.forename: V
authors.initials: V
authors.lastname: Magno
authors.forename: E
authors.initials: E
authors.lastname: Dias
authors.forename: P
authors.initials: P
authors.lastname: Crusius
authors.forename: A
authors.initials: A
authors.lastname: d'Avila
authors.forename: C
authors.initials: C
authors.lastname: Campos
authors.forename: M
authors.initials: M
authors.lastname: Costa
authors.forename: M
authors.initials: M
authors.lastname: Höblik
authors.forename: C
authors.initials: C
authors.lastname: Marc
authors.forename: R
authors.initials: R
authors.lastname: Marroni
authors.forename: K
authors.initials: K
authors.lastname: Syrjänen
mesh_terms: D000293:Adolescent; D000328:Adult; D001938:Brazil; D003075:Coitus; D005260:Female; D006801:Humans; D065006:Papanicolaou Test; D027383:Papillomaviridae / Q000145:classification / Q000276:immunology*; D030361:Papillomavirus Infections / Q000276:immunology* / Q000517:prevention & control; D016133:Polymerase Chain Reaction; D012307:Risk Factors; D002583:Uterine Cervical Neoplasms / Q000209:etiology* / Q000276:immunology; D014626:Vaginal Smears; D014765:Viral Vaccines / Q000276:immunology
chemical_list: D014765:Viral Vaccines